Skip to main content

Table 2 Comparison of MRI findings between controlled and poorly controlled patients

From: Assessment of the response to antiepileptic drugs in epileptic patients with structural lesion(s) on neuroimaging

 

Total (n = 165)

Controlled (< 1 seizure per month), n = 40

Uncontrolled (≥ 1 seizure per month), n = 125

P value

Type of lesion

Cerebromalatic lesion

53 (32.1%)

17 (32.1%)

36 (67.9%)

0.106

Atrophic lesion

21 (12.7%)

3 (14.3%)

18 (85.7%)

0.254

Cystic lesion

19 (11.5%)

5 (26.3%)

14 (73.7%)

0.782

Cerebral infarction

6 (3.6%)

2 (33.3%)

4 (66.7%)

0.633

Vascular malformation

12 (7.3%)

6 (50%)

6 (50%)

0.072

Tumors

15 (9.1%)

2 (13.3%)

13 (86.7%)

0.527

TSC

16 (9.7%)

3 (18.8%)

13 (81.3%)

0.763

MCD

12 (7.3%)

0 (0%)

12 (100%)

0.040*

Hippocampal sclerosis

11 (6.7%)

2 (18.2%)

9 (81.8%)

0.627

Hemisphere involved

Right

56 (33.9%)

15 (26.8%)

41 (73.2%)

0.585

Left

78 (47.3%)

19 (24.4%)

59 (75.6%)

0.974

Bilateral

31 (18.8%)

6 (19.4%)

25 (80.6%)

0.481

Site (lobe)

Frontal

40 (24.2%)

11 (27.5%)

29 (72.5%)

0.581

Temporal

56 (33.9%)

15 (26.8%)

41 (73.2%)

0.585

Parieto-occipital

33 (20%)

7 (21.2%)

26 (78.8%)

0.650

Hemiatrophy

17 (10.3%)

3 (17.6%)

14 (82.4%)

0.765

Topographical distribution

Cortical

32 (19.4%)

5 (15.6%)

27 (84.4%)

0.205

Subcortical

27 (16.4%)

8 (29.6%)

19 (70.4%)

0.475

Cortical + subcortical

89 (53.9%)

24 (27%)

65 (73%)

0.377

Subependymal

10 (6.1%)

3 (30%)

7 (70%)

0.706

Periventricular

7 (4.2%)

0 (0%)

7 (100%)

0.197

Number of lesions

Single

132 (80%)

35 (26.5%)

97 (73.5%)

0.173

Multiple

33 (20%)

5 (15.2%)

28 (84.8%)

  1. MCD malformations of cortical development, TSC tuberous sclerosis complex
  2. *P value < 0.05 is significant, and P value < 0.01 is highly significant